HARCP

HEROIN ADDICTION AND
RELATED CLINICAL PROBLEMS

The official journal of
EUROPAD - European Opiate Addiction Treatment Association
WFTOD - World Federation for the Treatment of Opioid Dependence
Editor: Icro Maremmani, MD - Pisa, Italy, EU
Associate Editors:
Thomas Clausen, MD - Oslo, Norway
Pier Paolo Pani, MD - Cagliari, Italy, EU
Marta Torrens, MD - Barcelona, Spain, EU
Statistical Editor:
Mario Miccoli, PhD - Pisa, Italy, EU

HARCP Archives

Browse by article Browse by volume    

Heroin Addiction and Related Clinical Problems: 2013, 15, 4 (pages: 21 - 24)

Long-term replacement of methadone by equipotent buprenorphine for male heroin addicts with methadone-induced hyperprolactinemia and sexual dysfunction. A case report.

Pacini M., Maremmani A.G.I., Rovai L., Bacciardi S., Rugani F., Maremmani I.

Summary: Background: sexual dysfunction is one of the aspects that limit the feasibility of methadone maintenance at adequate dosages that aims to suppress cravings for street opiates. One reason for this is that sexual disorders are likely to be related to opiate-induced elevated serum prolactin levels. Aim: to provide evidence that buprenorphine, at μ-equivalent dosages, can facilitate control over craving and psychopathological discomfort, without any major increase in serum prolactin. Materials and Methods: case report presentation. Results: buprenorphine, a partial μ-receptor agonist, is resorted to as a replacement for methadone, for a subject suffering from hyperprolactinaemia during the maintenance phase. Conclusions: buprenorphine may be a preferable option for low-craving heroin addicts who suffer from methadone-induced hyperprolactinaemia.

 

EUROPAD - European Opiate Addiction Treatment Association
Brussels, Belgium, EU
P. IVA 01681650469 – Codice Fiscale 94002580465 Reserved Area
Tel/Phone: 0584 - 790073 - Email: info@heroinaddictionrelatedclinicalproblems.org
Start of page